Related Experiment Videos
[Thromboembolic disease and cancer]
1Service de Pneumologie-Réanimation, Hôpital Laennec, Paris.
Presse Medicale (Paris, France : 1983)
|December 3, 1994
Summary
Cancer patients have an increased risk of thrombosis due to hemostatic anomalies and other risk factors. Anticoagulant therapy shows disappointing results, necessitating new treatment strategies for cancer-associated thromboembolism.
Area of Science:
- Hematology
- Oncology
- Thrombosis Research
Context:
- Cancer patients exhibit numerous hemostatic, coagulation, and fibrinolysis abnormalities predisposing them to thrombosis.
- Thromboembolism can be an early or presenting sign of cancer, and is more common in patients with idiopathic recurrent venous thrombosis.
Purpose:
- To review the hemostatic anomalies associated with cancer and their link to thrombosis.
- To evaluate the efficacy and safety of current anticoagulant therapies in cancer patients.
- To highlight the need for novel therapeutic approaches for thromboembolism in this population.
Summary:
- Cancer is linked to prothrombotic states through various mechanisms, increasing thromboembolism risk.
- Anticoagulant therapy, specifically vitamin K antagonists, has shown suboptimal outcomes with high rates of recurrent thrombosis and severe hemorrhage.
- The findings underscore the urgent need for clinical trials assessing new anticoagulation strategies in cancer patients.
Impact:
- Improved understanding of cancer-thrombosis links can guide clinical management.
- Highlights limitations of current treatments, driving research into more effective anticoagulation.
- Aims to reduce the morbidity and mortality associated with thromboembolic events in oncology patients.